We are improving the lives of people suffering from mental illness and substance use disorders
What we do
HQ & Pipeline
Digital Therapeutics
Discover our story
Key News
JULY 14, 2022
Q2 Interim Report - Good tailwind in the financial development
JULY 13, 2022
Deprexis® reimbursed under the US Veterans Affairs Federal Supply Schedule
JULY 6, 2022
Invitation to presentation of the Q2 Interim Report on July 14 at 2 pm
Listed on Nasdaq Stockholm´s mainlist
Orexo is listed on Nasdaq Stockholm´s mainlist, Mid Cap, (ORX), and can be traded in the US at the OTCQX Market (ORXOY).
MODIA® - our digital therapy for opioid dependence
- to be used along with pharmaceuticals
- 6 months treatment
- grounded in cognitive behavioral therapy techniques
- available 24/7
- ongoing clinical trial incl. up to 400 patients
News Flow
Orexo Social
@OrexoABpubl
19 July 2022
Soon a week ago. #orexo/#deprexis + Veterans Affairs #depression #digitalhealth pic.twitter.com/6ilWJaduJZ
@OrexoABpubl
18 July 2022
Dagens @SvDNaringsliv - en sammanfattning av Q2s finansiella utveckling. #orexo pic.twitter.com/Im2mIxOW4V
@OrexoABpubl
15 July 2022
Färsk intervju där hälsovårdsanalytikern Klas Palin på Erik Penser Bank för en dialog med #orexos VD Nikolaj Sorens… https://t.co/KRdU1tK3vT
Financial Snapshot
Group net revenues
597 MSEK
LTM1
Group EBITDA
-126 MSEK
LTM1
US Pharma segment EBIT
312 MSEK
LTM1
Cash position
468 MSEK
Q2 2022
1 Last Twelve Months, Q321-Q222, for more information about financial development Link